RANCHO CUCAMONGA, Calif. - Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), currently trading near its 52-week low but showing strong financial health according to InvestingPro analysis, announced ...

Additionally, the company reported a 20% increase in sales of Primatene Mist, signaling strong market demand for this product. This article was generated with the support of AI and reviewed by an ...

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ®, BAQSIMI ®, Primatene MIST ®, REXTOVY TM, Amphadase ®, and Cortrosyn ®, are the ...

Inhaler Epinephrine (medication) Salbutamol Nosebleed Glycated Hemoglobin Human Nose Glp-1 Receptor Agonist Hot Flash Esophagus Barrett's Esophagus Esophageal Cancer Ketoconazole Selenium ...

Despite these financial challenges, the company experienced a 20% increase in sales of Primatene Mist, indicating strong market demand.

Despite these financial challenges, the company experienced a 20% increase in sales of Primatene Mist, indicating strong market demand. Furthermore, the FDA accepted Amphastar’s Biologics License ...

Objectives This study explored the knowledge and awareness of Dutch patients, healthcare professionals (HCPs) and healthcare insurers on the climate impact of inhalers as well as (factors influencing) ...

Amphastar Pharmaceuticals' first quarter results saw revenue remain flat compared to last year and fall slightly short of Wall Street’s projections, while non-GAAP earnings per share came in ...